2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1452

18 F-FDG PET Imaging: An In Vivo quantitative Drug Screening Tool for Novel Antiinflammatory Therapies
Abstract Number: 3149

“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Abstract Number: 1540

“I Am Always in Pain Somewhere”: Continuing Unmet Need in Rheumatoid Arthritis
Abstract Number: 1249

“There Are Still a Lot of Things That I Need”: A Qualitative Study Exploring Opportunities to Improve the Health Outcomes of First Nations People with Arthritis Seen at an on-Reserve Outreach Rheumatology Clinic
Abstract Number: 1145

#Rheumjc: Impact of Invited Authors on a Twitter Based Rheumatology Journal Club
Abstract Number: 2969

10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Abstract Number: 3210

10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes
Abstract Number: 2285

12/15-Lipoxygenase Inhibition By ML351 Protects Against Uric Acid Crystal-Induced Acute Arthritis in Mice
Abstract Number: 89

2015 ACR/ARHP Workforce Study (WFS): Adult Rheumatology Specialists in the United States: Effect of Gender and Generation
Abstract Number: 1960

2015 ACR/ARHP Workforce Study in the U.S.: The Role of Graduate Medical Education (GME) in Adult Rheumatology
Abstract Number: 927

2015 ACR/ARHP Workforce Study in the United States: Pediatric Rheumatologist Supply and Demand Projections for 2015-2030
Abstract Number: 928

2015 ACR/ARHP Workforce Study in the United States: A Maldistribution of Adult Rheumatologists
Abstract Number: 93

2015 ACR/ARHP Workforce Study in the United States: Adult Rheumatologist Supply and Demand Projections for 2015-2030
Abstract Number: 997

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria
Abstract Number: 1045

2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis

1
2
3
…
219
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].